clinical trial · NCT03843359
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
NeoplasmsGSK3745417Dostarlimab
brief summary
This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.
started
Mar 12, 2019
primary completion
Apr 4, 2024
completion
Jan 9, 2026
last updated
Aug 3, 2026
official title
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol